Skip to main content
. 2023 May 4;41(10):1164–1172. doi: 10.1007/s11604-023-01439-6

Fig. 2.

Fig. 2

Comparison of the rates of grade 3 or more adverse events between the 2D-IGBT and 3D-IGBT groups. a G3-5 urinary tract adverse events free survival, b G3-gastrointestinal adverse events free survival